| Monoclonal Antibodies as Therapeutics: The Path from Target ID to Clinical Trials |
|
|
|
Monday, March 31 2008, 16:00 - 16:50 |
|
Hits : 19904 |
|
Presentation 2: 4:00 pm, Monday Mar.
31 Room 100 PHSC
William R. Usinger, Ph. D.
Director of Research
Antibody and Protein Therapeutics
NOVARTIS, Inc., Emeryville, CA
Title: Monoclonal Antibodies as Therapeutics: The Path from Target
ID to Clinical Trials
 Dr. William R. Usinger received his doctorate in
immunology at the University of Wisconsin, Madison in 1980, and was an NIH
postdoctoral fellow in the laboratory of Robert Mishell at the University of
California, Berkeley, where his research focused on the generation of
hybridoma-derived monoclonal antibodies to bacterial polysaccharides. In
1983 he founded Immusine Inc., a biotechnology company and independent research
laboratory for monoclonal antibody production and immunoassay
development. In the ensuing years Dr. Usinger continued his involvement
with San Francisco Bay Area biotechnology: Vice President, Founder &
Director of Research at Metabolex, Inc. (1989-1994); Vice President of
Preclinical Development at PlasmaSeal, Inc. (1994-1996); Visiting Scientist at
Children's Hospital Oakland Research Institute (1996-1998); Director of
Immunobiology at FibroGen, Inc. (1998-2005); Director of Research, Novartis
Corporation (2005-present). In his current position Dr. Usinger
directs a multi-discipline effort to identify and characterize monoclonal
antibody drug candidates for new oncology targets. His scientific
accomplishments include the development of novel laboratory inventions,
technologies, assays, cell lines and more than 60 scientific publications.
|
|
Location: Room 100 PHSC |
